•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Agomab to Participate in Upcoming Investor Conferences
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease Transcript
Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
AgomAb Therapeutics NV (NASDAQ:AGMB) Stock Has Average Target Price of $37.50
AgomAb Therapeutics: Building A New Treatment Layer In Fibrosis
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Agomab to Participate in Upcoming Investor Conferences
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
AgomAb Therapeutics: High Risk, High Reward Stock
Agomab Announces Results of Annual General Meeting
Agomab Announces Results of Annual General Meeting
Agomab to Participate in Upcoming Conferences
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
Already premium?